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Abstract: This work aims to validate the Polar H7 heart rate (HR) sensor for heart rate variability
(HRV) analysis at rest and during various exercise intensities in a cohort of male volunteers with
different age, body composition and fitness level. Cluster analysis was carried out to evaluate how
these phenotypic characteristics influenced HR and HRV measurements. For this purpose, sixty-
seven volunteers performed a test consisting of the following consecutive segments: sitting rest, three
submaximal exercise intensities in cycle-ergometer and sitting recovery. The agreement between
HRV indices derived from Polar H7 and a simultaneous electrocardiogram (ECG) was assessed
using concordance correlation coefficient (CCC). The percentage of subjects not reaching excellent
agreement (CCC > 0.90) was higher for high-frequency power (PHF) than for low-frequency power
(PLF) of HRV and increased with exercise intensity. A cluster of unfit and not young volunteers
with high trunk fat percentage showed the highest error in HRV indices. This study indicates that
Polar H7 and ECG were interchangeable at rest. During exercise, HR and PLF showed excellent
agreement between devices. However, during the highest exercise intensity, CCC for PHF was lower
than 0.90 in as many as 60% of the volunteers. During recovery, HR but not HRV measurements were
accurate. As a conclusion, phenotypic differences between subjects can represent one of the causes
for disagreement between HR sensors and ECG devices, which should be considered specifically
when using Polar H7 and, generally, in the validation of any HR sensor for HRV analysis.
Keywords: electrocardiography; wearable devices; HRV analysis; cluster analysis; exercise test
1. Introduction
Heart rate (HR) variability (HRV) is the oscillation in the intervals between consecutive
heartbeats (RR intervals) [1]. In the last decades, the use of HRV has been popularized,
since it allows assessing cardiac autonomic modulation using simple and non-invasive
techniques. In general, lower HRV has been associated with poorer prognosis in different
clinical conditions, while higher HRV, especially regarding high-frequency oscillations, has
been associated with better health. In particular, reduced HRV has been reported in several
cardiovascular diseases and has been used for risk stratification, confirming its value as a
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predictor of total and cardiac mortality [2–4]. Also, low HRV has been described in a wide
range of non-cardiovascular diseases, including psychiatric disorders such as depression,
anxiety or schizophrenia [5].
Environmental and behavioral factors influence HRV [6]. In psychology, HRV is com-
monly used due to its modulation by mood states, emotions or cognitive capacity [5].
Likewise, HRV is a useful measurement in the sports field since it is sensitive to changes in
fitness, fatigue and performance [7]. Healthy habits like exercise, balanced diet, mindful-
ness or psychological interventions have been shown to increase HRV measures indexing
vagal function [5,6]. Additionally, non-modifiable factors, such as age or sex, also influence
the autonomic regulation of the heart, with HRV having been reported to progressively
decline with age and to present enhanced high-frequency oscillations and attenuated low-
frequency oscillations in females as compared to males [8]. Because of these high inter-
and intra-individual variations in HRV, it is key to use wearable devices validated for
HRV analysis that can allow for precise interpretation of cardiac responses to different
autonomic states.
A recent systematic review and meta-analysis showed that HRV measurements de-
rived from portable devices are generally accurate when compared to lab-based electro-
cardiogram (ECG) [9]. Given the low cost of HR monitors it is not surprising that they
are widely used by practitioners and researchers. Particularly, Polar Electro Oy (Kempele,
Finland) is one of the most well-established brands in HR monitoring, with Polar H7/H10
HR sensors having been validated both at rest and during exercise [10–12]. Nevertheless,
previous Polar validation studies have been carried out in small groups of young, lean,
healthy and physically fit volunteers [10–12]. However, the device is commonly used by
individuals with various phenotypic characteristics, regardless of how these may affect the
accuracy of the measurements [13,14]. In the meta-analysis described in [9], the absolute
error of portable devices was found to vary with the evaluated HRV metric, tilt/recovery
position and the percentage of women in the study sample. The characteristics of the
subjects and their influence on the measurements provided by portable devices have not
been analyzed yet.
The ECG records the electrical activity of the heart using electrodes placed on the
surface of the body. Therefore, differences between measurements from HR sensors and
ECG could vary depending on the characteristics of the population under study. To start
with, the age-related myocardial fibrosis present in the cardiac tissue, the amount of
subcutaneous fat or the electrode placement are expected to affect the voltage tracings [15].
Additionally, voltage will be influenced by ventricular size or mass, as observed when
comparing trained athletes with non-athletes [16]. Accordingly, some groups of subjects
such as men, athletes or black/African have been reported to have higher QRS voltage
and, consequently, RR intervals become easier to be detected [16]. On the other hand,
obesity, older age and sedentary lifestyle may cause lower voltage, which may result in
lower accuracy of portable devices. In particular, under such circumstances, some heart
beats can be misdetected and, while this may not considerably affect mean HR, it may
notably hamper HRV assessment. For these reasons and in light of previous studies, we
hypothesized that when the quality of the Polar H7 ECG is compromised by high noise
during intense exercise and/or by specific phenotypic characteristics of the subjects, HRV
measures can be distorted, particularly those related to high-frequency power [17].
The purpose of the present study was to evaluate the validity of HRV analysis derived
from RR intervals recorded by Polar H7 HR sensor at rest and during exercise and recovery
in different phenotype groups based on age, body composition and fitness level.
2. Materials and Methods
2.1. Subjects
A total of sixty-seven males agreed to participate in the study. The sample consisted
of three groups of volunteers: 22 young adults (20–30 years old), 22 middle-aged adults
(40–50 years old) and 23 older adults (60–70 years old). Only subjects within the prede-
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fined age ranges were included in the study. Subjects were excluded from the study if
they were going through an acute disease, were suffering from heart diseases (e.g., heart
failure or atrial fibrillation), were on cardiac medication or presented any clinical condition
contraindicating physical exercise. However, subjects who were overweight, sedentary or
suffering from chronic diseases such as hypertension, diabetes or hypercholesterolemia
were included in the study, because of their high prevalence in the society. Table 1 shows
the descriptive characteristics of the three age groups. The study was approved by the
ethical committee for clinical research of Aragón (ID of the approval: PI17/0409), and was
conducted by adhering to the Declaration of Helsinki. After a clear explanation of the
potential risks of the study, all volunteers provided written informed consent.
Table 1. Descriptive characteristics of the three age groups.





Age (years) 25.46 ± 2.85 43.17 ± 3.32 63.97 ± 2.79
Height (m) 1.75 ± 0.06 1.77 ± 0.06 1.71 ± 0.05
Weight (kg) 72.01 ± 11.92 78.19 ± 10.30 76.31 ± 7.76
BMI (m/kg2) 23.43 ± 2.95 25.02 ± 2.83 26.21 ± 2.84
Body fat (%) 15.25 ± 5.59 19.69 ± 5.65 23.38 ± 5.17
Trunk fat (%) 16.31 ± 6.32 21.29 ± 6.38 25.69 ± 6.42
PWC80% (W/kg) 2.00 ± 0.64 2.01 ± 0.58 1.73 ± 0.65
Values are expressed as mean ± standard deviation (SD). BMI = Body mass index; PWC80% = Physical Work
Capacity at 80% of maximum HR (208 − 0.7 ∗ age in years) in watts/kg bodyweight.
2.2. Procedure
All subjects completed one test session. Prior to the test, they were asked to adhere to
the following instructions [18]: (1) avoid exercise or strenuous physical activity the day
before the test; (2) drink plenty of fluids over the 24-h period preceding the test; (3) get
an adequate amount of sleep (6–8 h) the night before the test; (4) avoid substances such
as tobacco, alcohol or stimulants (caffeine, theine, taurine, etc.) in the 8 h before the test;
(5) avoid food intake for 3 h prior to performing the test; and (6) wear comfortable, loose-
fitting clothing. Subjects’ skin was prepared by using a razor to remove any hair from
the electrode sites, cleaning the skin with alcohol and drying it with a gauze. A 12-lead
high-resolution Holter ECG was acquired, with the 10 electrodes placed as indicated by
the manufacturer (H12+, Mortara Instrument, Milwaukee, WI, USA), ensuring that they
did not interfere with the HR sensor strap (Polar H7, Polar Electro Oy).
The test was conducted in an environmentally controlled room (22–23 ◦C), between
16:00–20:00, and was divided into 3 consecutive segments: resting (SREST), cycling (SCY) and
recovery (SREC). During SREST, volunteers were monitored while seated at rest for 5 min,
without any movement or talking. A period of 2–3 min was established to change from
the chair to the cycle-ergometer, namely from SREST to SCY, during which the subject rode
the electrically braked cycle-ergometer (Ergoselect 200 K, Ergoline; Bitz, Germany) at 50 W
workload and chose a cadence which was maintained during the entire test according to
the workload and cadence displayed in the cycle-ergometer screen. SCY was a submaximal
cycle-ergometer test divided into three stages lasting 5 min each. In order to avoid a
maximal exercise test, the maximum heart rate (HRmax) was estimated for each subject by
using the formula defined by Tanaka et al. HRmax = 208 − 0.7 ∗ age (years) [19]. Workload
was adjusted during each stage to 60, 70 and 80% of HRmax, with these stages denoted
as SCY60, SCY70 and SCY80, respectively. Finally, during SREC, volunteers remained seated
again for 5 min without any movement or talking. Figure 1 shows an example of the
temporal evolution of RR intervals from a subject throughout the entire test.
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2.3. Data Recording
Subjects self-reported their birth date, current diseases and medication. The anthropo-
metric characteristics of the subjects were assessed. Stature was measured to the nearest
0.001 m using a portable stadiometer (SECA 225, Hamburg, Germany), with subjects
standing with their scapula, buttocks and heels resting against a wall, the feet with the
heels touching, forming a 45◦ angle and the head in the Frankfort’s plane. A portable
body composition analyzer (TANITA BC-418MA; Tanita Corp., Tokyo, Japan) was used
to measure the body mass to the nearest 0.1 kg, with underwear and after urination.
TANITA BC-418MA was also used to estimate the percentage of body fat and trunk fat
(r = 0.87, p < 0.001 vs. dual-energy X-ray absorptiometry) [20]. Body mass index (BMI) was
calculated dividing weight in kilograms by height in squared meters.
Beat-to-beat RR intervals with 1-ms resolution were obtained using a Polar V800 HR
monitor simultaneously with a Polar H7 chest Soft Strap (Polar Electro Oy, henceforth
referred to as PolarH7). Concomitantly, a 12-lead ECG was recorded at a sampling rate
of 1000 Hz using a high-resolution Holter device (H12+, Mortara Instrument, henceforth
referred to as ECG and used here as a reference).
VO2max can be estimated from submaximal exercise tests, a safe and feasible method
showing good validity against maximal tests (correlation coefficients: 0.69 to 0.98) [21].
Rather than commonly used tests with stages of short or variable duration, an ad-hoc test
with 5-min stages was defined to allow reliable estimation of the low-frequency power of
HRV. This enabled assessment of HRV response to increased sympathetic activity with each
cycling stage [22]. Cardiorespiratory fitness was assessed using the approach of “Physical
Work Capacity” (PWC). PWC in watts was measured during SCY80 of the submaximal
cycle-ergometer test and was subsequently divided by the subject’s body weight (PWC80%
in W/kg). Alternatively to the use of fixed HR thresholds, this method incorporates the
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age-dependent decline of HRmax [23,24] and has been previously used as an objective
assessment of cardiorespiratory fitness [25,26].
2.4. Data Analysis and Processing
Raw RR interval time series, RRP (i), recorded by PolarH7 were downloaded from the
“Polar Flow” web platform. RR interval time series from the ECG, RRE (i), were extracted
using a multi-lead approach by a wavelet-based detector [27] with optimized parameters
for noisy environments as described in [28]. Each beat detection was manually verified by
an operator with a dedicated interface.
The delay between the RR interval series RRP (i) and RRE (i) was estimated as the time
lag maximizing their cross-correlation over the first 3 min of the test when the subject is
relaxed. Then, both series were synchronized by compensating for this delay. Since the two
RR interval series can have different lengths, due to, e.g., wrong or missed beat detections
in the Polar data, an algorithm was developed to match the RR intervals from both series,
thus allowing characterization of the agreement between the paired series RRP (ip) and
RRE (ip), where ip refers to the indices of beats that are matched in the two series.
2.5. Heart Rate Variability
HRV indices were obtained by algorithms specifically developed and previously
published by our research group using MATLAB version R2017a (MATLAB, MathWorks
Inc., Natick, MA, USA) [17,27–30].
2.5.1. Temporal Domain
The following temporal HRV indices were studied [1]: mean HR (MHR), standard
deviation of normal-to-normal RR intervals (SDNN) and root mean square of successive
differences of adjacent normal-to-normal RR intervals (RMSSD). MHR was obtained as the
inverse of the mean of the RR intervals. SDNN is considered a measure of the total power
of HRV and was calculated from the standard deviation of the NN intervals, i.e., normal
RR intervals after correcting for ectopic beats [29]. RMSSD is a measure of short-term
variability and was computed by the root mean square of successive differences between
adjacent NN intervals. These indices were obtained from RRP (i) and RRE (i) in each
segment of the test.
2.5.2. Frequency Domain
The instantaneous HR signal, dHR(n), was derived from both RRP (i) and RRE (i) and
sampled at 4 Hz. The integral pulse frequency modulation (IPFM) model was used while
dealing with the presence of ectopic beats [29]. This signal was high-pass-filtered (0.03 Hz)
to remove the very low-frequency components, dMHR(n), and it was also corrected by it:
m(n) = (dHR(n)− dMHR(n))/dMHR(n) [30].
The smoothed pseudo Wigner–Ville distribution (SPWVD) was applied to m(n) to
estimate its time-varying spectrum. Time and frequency smoothing windows were chosen
as described in [17]. The instantaneous power in the low-frequency band, PLF (n), was
extracted integrating the SPWVD from 0.04 to 0.15 Hz for each time instant. The instanta-
neous power in the high-frequency band, PHF (n), was computed in a band centered on
the respiratory frequency with a bandwidth of 0.25 Hz. Figure 2 shows an example of
dHR(n), PLF (n) and PHF (n) obtained from RRE. In some analyses, mean PLF and PHF were
calculated from PLF (n) and PHF (n) for each segment of the test.
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2.6. Statistical Analysis
The normality of data was checked with the Kolmogorov-Smirnov test. Since the
data distribution violated the assumption of normality of the parametric tests, and such a
condition was not achieved by commonly employed transformations, a non-parametric
analysis was performed. Descriptive values are presented as mean ± standard deviation
(SD) and HRV values are reported as median and interquartile range. Statistical analyses
were performed using IBM SPSS (version 25; Chicago, IL, USA). The significance level was
set at p ≤ 0.05.
Wilcoxon test for paired samples, the non-parametric equivalent of the paired samples
t-test, was used to determine differences between the temporal domain HRV data obtained
from PolarH7 and from ECG. The magnitude of the differences was calculated by deter-
mining the effect size (ES): ES = Z/
√
n where Z represents the Z-score for the Wilcoxon
statistic and n is the total number of observations [31]. Differences were considered small
when ES < 0.2, small to medium when ES = 0.2–0.5, medium to large when ES= 0.5–0.8 and
large when ES > 0.8 [32].
Lin’s concordance correlation coefficient (CCC) was used to study the agreement
between the following PolarH7-derived and ECG-derived signals: RR (ip), PHF (n) and
PLF (n). CCC determines how much the observed data deviate from the perfect concor-
dance line at 45◦ on a square axis scatter plot [33]. CCC was evaluated in each segment
(SREST, SCY60, SCY70, SCY80 and SREC). A CCC value greater than 0.90 was considered “ex-
cellent” [34] and the percentage of subjects with CCC values below this threshold was
reported for each segment.
Cluster analysis was performed to identify groups of subjects with similar character-
istics in terms of the following three variables of interest: age, body composition (trunk
fat percentage) and fitness level (PWC80%). Trunk fat percentage was selected among all
body composition variables, since it is the most specific to the electrode placement area.
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Following the methodology described in previous studies [35,36], two types of cluster anal-
yses were combined: hierarchical clustering (Ward’s method) and k-means clustering. First,
individual and multivariate outliers (according to Mahalanobis distance) were detected to
reduce the sensitivity of the Ward’s method to outliers. Second, hierarchical cluster analysis
was used, as the number of clusters in the data were unknown beforehand. Examination of
dendrograms showed that a four-cluster solution produced good differentiation between
groups. Finally, k-means cluster was performed with four possible solutions. Compared
to hierarchical methods, k-means cluster analysis is considered less sensitive to outliers
and has been found to result in greater within-cluster homogeneity and between-cluster
heterogeneity [35].
To assess differences in the percentage of error for each HRV index between the
four cluster groups, a Kruskal-Wallis test (non-parametric equivalent of one-way analysis
of variance, ANOVA) with Bonferroni correction was performed. The Dunn-Bonferroni
post hoc method was used for pairwise comparisons. The relative error in HRV indices
was calculated as the absolute error of the PolarH7 with respect to the ECG measurement
divided by the reference ECG measurement, e.g., (SDNNECG − SDNNPolarH7)/SDNNECG,
which was then multiplied by 100 to obtain the percentage of error (%Error). In the case
of the frequency HRV variables, %Error was calculated from the mean value for each





/(n + 1)), where H stands for the Kruskal-Wallis test statistic and n is
the total number of observations [31].
3. Results
Table 2 shows the descriptive characteristics of the 4 cluster groups, which were
described as CLUSTER A (High PWC80%), CLUSTER B (Low PWC80% and low age),
CLUSTER C (Low PWC80%, high age and medium trunk fat percentage) and CLUSTER D
(Low PWC80%, high age and high trunk fat percentage).












Age (years) 38.99 ± 13.31 B,D 24.35 ± 2.20 A,C,D 52.61 ± 10.20 B 57.47 ± 12.23 A,B <0.001 * 0.586
Height (m) 1.77 ± 0.05 D 1.72 ± 0.06 1.74 ± 0.06 1.72 ± 0.07 A 0.020 0.149
Weight (kg) 72.65 ± 9.13 69.18 ± 12.27 D 76.32 ± 7.13 82.72 ± 8.78 B 0.007 0.182
BMI (m/kg2) 23.00 ± 2.24 D 23.23 ± 2.77 D 25.17 ± 1.40 28.04 ± 2.79 A,B <0.001 * 0.430
Body fat (%) 14.09 ± 4.11 C,D 15.45 ± 4.54 D 20.40 ± 2.36 A,D 27.67 ± 2.42 A,B,C <0.001 * 0.743
Trunk fat (%) 14.76 ± 5.11 C,D 16.64 ± 5.03 D 22.19 ± 2.86 A,D 30.69 ± 2.12 A,B,C <0.001 * 0.725
PWC80% (W/kg) 2.73 ± 0.39 B,C,D 1.61 ± 0.37 A 1.79 ± 0.28 A,D 1.35 ± 0.22 A,C <0.001 * 0.704
Values are expressed as mean ± standard deviation (SD). BMI = Body mass index; PWC80% = Physical Work Capacity at 80% of HRmax
(208 − 0.7 ∗ age in years) in watts/kg bodyweight. Clusters were based on: age, body composition (trunk fat percentage) and fitness
level (PWC80%). * = Significant differences between clusters (p ≤ 0.05, Kruskal-Wallis test). A = Different to CLUSTER A; B = Different to
CLUSTER B; C = Different to CLUSTER C; D = Different to CLUSTER D.
Table 3 shows the values of HRV indices obtained from PolarH7 and ECG. Mean
PLF and PHF were calculated from PLF (n) and PHF (n) for each segment (differently from
Table 4, where the instantaneous series were used). Wilcoxon test for paired samples
revealed that PHF and temporal domain HRV indices (MHR, SDNN and RMSSD) were
lower at all cycling stages (SCY60, SCY70 and SCY80) when measured by PolarH7, with PLF
being lower at the highest intensity (SCY80) when measured by PolarH7. The magnitude of
all these differences was small to medium, i.e., 0.2–0.5 according to the effect sizes.
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Table 3. HRV indices obtained from PolarH7 and ECG data (n = 67).
PolarH7 ECG p ES
SREST
PLF (e−4) 9.78 (3.88 to 24.74) 9.76 (3.85 to 24.78) 0.074 0.155
PHF (e−4) 5.77 (2.30 to 10.91) 5.74 (2.22 to 10.84) 0.067 0.159
MHR (bpm) 62.55 (53.25 to 71.95) 62.84 (53.36 to 72.00) <0.001 * 0.378
SDNN (ms) 60.27 (40.50 to 75.22) 60.28 (40.33 to 75.26) 0.570 0.049
RMSSD (ms) 39.48 (22.48 to 60.04) 39.26 (22.39 to 60.66) 0.336 0.083
SCY60
PLF (e−4) 1.17 (0.62 to 2.01) 1.17 (0.65 to 2.23) 0.112 0.137
PHF (e−4) 0.51 (0.26 to 1.29) 0.86 (0.44 to 2.07) <0.001 * 0.419
MHR (bpm) 106.00 (100.45 to 112.91) 106.66 (100.75 to 113.17) <0.001 * 0.433
SDNN (ms) 15.94 (12.06 to 20.77) 16.21 (12.85 to 20.32) 0.010 * 0.222
RMSSD (ms) 6.48 (4.34 to 8.51) 8.38 (5.67 to 10.65) <0.001 * 0.482
SCY70
PLF (e−4) 0.45 (0.21 to 0.87) 0.46 (0.22 to 0.88) 0.851 0.016
PHF (e−4) 0.30 (0.15 to 0.55) 0.41 (0.24 to 0.75) <0.001 * 0.377
MHR (bpm) 124.24 (115.77 to 130.89) 124.32 (115.76 to 130.92) <0.001 * 0.482
SDNN (ms) 10.22 (8.19 to 12.93) 10.48 (8.40 to 13.10) 0.001 * 0.280
RMSSD (ms) 3.74 (2.96 to 4.91) 4.37 (3.64 to 6.68) <0.001 * 0.443
SCY80
PLF (e−4) 0.13 (0.09 to 0.23) 0.18 (0.10 to 0.26) <0.001 * 0.364
PHF (e−4) 0.23 (0.14 to 0.36) 0.37 (0.25 to 0.66) <0.001 * 0.362
MHR (bpm) 141.01 (130.62 to 148.81) 141.09 (130.69 to 149.05) <0.001 * 0.451
SDNN (ms) 8.11 (6.20 to 9.92) 8.10 (6.34 to 10.65) <0.001 * 0.378
RMSSD (ms) 2.90 (2.32 to 3.90) 3.75 (3.16 to 5.52) <0.001 * 0.405
SREC
PLF (e−4) 4.75 (1.83 to 10.25) 4.59 (1.88 to 9.97) 0.881 0.015
PHF (e−4) 2.06 (0.65 to 4.71) 2.12 (0.82 to 4.70) 0.308 0.102
MHR (bpm) 99.76 (90.76 to 112.15) 98.39 (90.12 to 111.35) 0.002 * 0.268
SDNN (ms) 33.11 (23.27 to 58.30) 33.67 (23.04 to 57.40) 0.094 0.147
RMSSD (ms) 12.87 (7.65 to 23.78) 12.90 (7.99 to 23.32) 0.603 0.046
Values are expressed as median and interquartile range. Segments are based on the test phases: resting (SREST), cycling (SCY) and recovery
(SREC). SCY was divided in three stages at 60, 70 and 80% of HRmax, denoted as SCY60, SCY70 and SCY80, respectively. PLF = low-frequency
power; PHF = high-frequency power; MHR = mean HR; SDNN = SD of the NN intervals; RMSSD = root mean square of successive
differences between NN intervals. ES = Effect size. * = Significant differences between devices (p ≤ 0.05, Wilcoxon test for paired samples).
Table 4. Agreement between devices in: RR (ip), PLF (n) and PHF (n). CCC mean and percentage of subjects not reaching
excellent agreement for each segment.
SREST SCY60 SCY70 SCY80 SREC
Whole sample
(n = 67)
RR (ip) 0.9929 (1%) 0.9560 (6%) 0.9467 (13%) 0.9319 (16%) 0.9612 (14%)
PLF (n) 0.9885 (1%) 0.9713 (4%) 0.9677 (9%) 0.9106 (19%) 0.8251 (30%)
PHF (n) 0.9813 (3%) 0.9494 (13%) 0.8858 (27%) 0.6661 (60%) 0.5262 (75%)
CLUSTER A
(n = 19)
RR (ip) 0.9970 (0%) 0.9844 (0%) 0.9472 (21%) 0.9243 (21%) 0.9778 (6%)
PLF (n) 0.9999 (0%) 0.9990 (0%) 0.9911 (5%) 0.9169 (16%) 0.7440 (47%)
PHF (n) 0.9982 (0%) 0.9645 (16%) 0.9316 (11%) 0.7970 (37%) 0.4859 (88%)
CLUSTER B
(n = 13)
RR (ip) 0.9828 (8%) 0.8996 (15%) 0.8690 (23%) 0.9258 (23%) 0.9473 (15%)
PLF (n) 0.9423 (8%) 0.8544 (23%) 0.9757 (8%) 0.8601 (15%) 0.8838 (15%)
PHF (n) 0.9284 (8%) 0.8710 (23%) 0.9112 (23%) 0.7455 (62%) 0.7402 (54%)
CLUSTER C
(n = 18)
RR (ip) 0.9943 (0%) 0.9363 (11%) 0.9665 (11%) 0.9035 (22%) 0.9615 (12%)
PLF (n) 0.9990 (0%) 0.9998 (0%) 0.9792 (6%) 0.9164 (28%) 0.7791 (31%)
PHF (n) 0.9909 (6%) 0.9670 (6%) 0.8906 (28%) 0.5914 (67%) 0.3843 (88%)
CLUSTER D
(n = 17)
RR (ip) 0.9945 (0%) 0.9884 (0%) 0.9844 (0%) 0.9751 (0%) 0.9541 (24%)
PLF (n) 0.9999 (0%) 0.9996 (0%) 0.9233 (18%) 0.9361 (18%) 0.9045 (24%)
PHF (n) 0.9929 (0%) 0.9739 (12%) 0.8100 (47%) 0.5381 (76%) 0.5366 (65%)
Values are expressed as CCC mean and (percentage of subjects under 0.9 threshold). Segments are based on the test phases: resting
(SREST), cycling (SCY) and recovery (SREC). SCY was divided in three stages at 60, 70 and 80% of HRmax, denoted as SCY60, SCY70 and SCY80
respectively. The characteristics of each cluster were the following: CLUSTER A = high fitness; CLUSTER B = low fitness and low age;
CLUSTER C = low fitness, high age and medium trunk fat percentage; CLUSTER D = low fitness, high age and high trunk fat percentage.
RR (ip) = paired RR interval series; PLF (n) = instantaneous low-frequency power; PHF (n) = instantaneous high-frequency power.
Table 4 shows CCC values for RR (ip), PLF (n) and PHF (n) and outlines the percentage
of subjects not reaching excellent agreement (CCC > 0.90) for each segment of the test. The
number of subjects not reaching excellent agreement was clearly higher for PHF (n) than for
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PLF (n) (χ2(degrees of freedom); χ2(1) = 45.52; p < 0.001), it increased with exercise intensity
(χ2(2) = 38.47; p < 0.001) and was lower during exercise than during SREC (χ2(1) = 42.31;
p < 0.001). When performing the analysis separately for each identified cluster, CLUSTER
A obtained the highest CCC values, with CLUSTER D being the group with less subjects
showing optimal agreement between devices in PHF (n). Due to the presence of noise in
the RRP (i) series during SREC, the instantaneous power could not be properly extracted in
4 volunteers and the final sample for SREC was N = 63.
Table 5 shows %Error for each HRV index. Kruskal-Wallis test demonstrated signif-
icant differences between clusters in PHF at SREST and during exercise (SCY70 and SCY80).
With regards to temporal domain HRV indices, SDNN showed significant differences
between groups at SREST and during exercise (SCY60 and SCY80) and RMSSD showed signif-
icant differences at the highest intensities (SCY70 and SCY80). Both for PHF and for temporal
domain HRV indices, CLUSTER D was the group with the highest %Error. The magnitude
of all these differences was small, i.e., <0.2 according to the effect sizes.












PLF 0.0 (−0.2 to 0.3) 0.2 (−0.3 to 0.6) 0.1 (−0.2 to 0.2) 0.3 (−0.1 to 0.4) 0.534 0.034
PHF −0.5 (−2.3 to 0.2) −0.2 (−0.7 to 0.4) −0.5 (−1.4 to 0.4) 0.5 (−0.3 to 2.0) 0.049 * 0.121
SDNN 0.0 (−0.2 to 0.5) B −0.1 (−0.8 to 0.0) A,D 0.0 (−0.2 to 0.2) 0.1 (0.0 to 0.2) B 0.021 * 0.147
RMSSD −0.2 (−1.0 to 0.3) −0.1 (−2.3 to 0.4) −0.1 (−1.3 to 0.4) 0.2 (−0.2 to 2.3) 0.150 0.081
SCY60
PLF 0.8 (−0.7 to 18.7) 0.0 (−0.8 to 1.3) 0.4 (−4.0 to 3.0) 0.8 (−0.5 to 4.4) 0.444 0.041
PHF 25.7 (10.3 to 48.3) 2.1 (−12.5 to 17.7) 21.7 (−2.4 to 44.6) 27.0 (10.9 to 65.6) 0.164 0.077
SDNN 0.1 (−2.5 to 0.9) D −0.2 (−1.2 to 1.4) 1.2 (−0.1 to 4.2) 2.2 (1.1 to 8.5) A 0.018 * 0.153
RMSSD 14.4 (4.6 to 32.4) 1.8 (−3.2 to 14.6) 21.7 (4.2 to 29.8) 15.8 (7.9 to 44.1) 0.266 0.060
SCY70
PLF 1.6 (−0.5 to 7.5) −0.2 (−2.8 to 0.9) −0.4 (−1.7 to 2.1) −0.6 (−7.8 to 2.8) 0.125 0.087
PHF 9.2 (−6.2 to 50.8) −0.9 (−42.6 to 25.6) C,D 25.3 (17.5 to 57.2) B 51.8 (14.5 to 71.7) B 0.007 * 0.186
SDNN 0.6 (−0.5 to 2.8) 0.2 (−1.4 to 1.6) 1.5 (−1.2 to 7.0) 2.3 (0.3 to 8.0) 0.104 0.093
RMSSD 15.4 (−2.0 to 29.5) 0.6 (−27.9 to 19.3) D 15.6 (14.2 to 36.5) 27.1 (14.2 to 56.0) B 0.010 * 0.172
SCY80
PLF 1.5 (−2.6 to 32.0) 2.8 (−1.0 to 3.6) 2.7 (−1.1 to 12.6) 5.9 (0.3 to 16.1) 0.596 0.029
PHF 31.6 (−27.4 to 87.7) −9.0 (−113.1 to 56.4) D 28.0 (8.5 to 45.2) 44.7 (37.2 to 77.7) B 0.047 * 0.121
SDNN 4.0 (−0.8 to 13.7) −0.4 (−2.9 to 6.1) 1.1 (−0.3 to 4.1) 5.7 (1.6 to 14.3) 0.050 * 0.119
RMSSD 19.2 (−9.9 to 67.0) 8.4 (−43.0 to 26.1) D 19.0 (4.7 to 32.7) 32.9 (22.1 to 58.2) B 0.028 * 0.137
SREC
PLF −0.4 (−33.8 to 0.1) 0.5 (−0.5 to 6.2) 0.2 (−17.6 to 3.9) 0.2 (−4.9 to 12.7) 0.161 0.105
PHF −1.6 (−8.2 to 5.8) 1.6 (0.1 to 5.9) −1.2 (−8.3 to 10.1) 9.3 (−0.2 to 37.2) 0.053 0.157
SDNN −0.1 (−0.9 to 0.1) 0.1 (−1.5 to 0.3) −0.1 (−1.0 to 0.4) 0.0 (−1.8 to 0.7) 0.933 0.007
RMSSD −0.9 (−2.3 to 2.0) 0.1 (−9.8 to 3.0) 1.5 (−1.4 to 5.5) 2.2 (−2.9 to 11.5) 0.226 0.068
Percentage error (%) values are expressed as median and interquartile range. The characteristics of each cluster were the following:
CLUSTER A = high fitness; CLUSTER B = low fitness and low age; CLUSTER C = low fitness, high age and medium trunk fat percentage;
CLUSTER D = low fitness, high age and high trunk fat percentage. Segments are based on the test phases: resting (SREST), cycling
(SCY) and recovery (SREC). SCY was divided in three stages at 60, 70 and 80% of HRmax, denoted as SCY60, SCY70 and SCY80 respectively.
PLF = low-frequency power; PHF = high-frequency power; SDNN= SD of the RR intervals; RMSSD = root mean square of successive
differences between NN intervals. * = Significant differences between clusters (p ≤ 0.05, Kruskal-Wallis test). A = Different to CLUSTER A;
B = Different to CLUSTER B; C = Different to CLUSTER C; D = Different to CLUSTER D.
4. Discussion
In this study, HRV analysis from RR intervals provided by PolarH7 at rest and during
various exercise intensities has been validated against the same analysis from a simulta-
neous ECG recording. Wilcoxon test showed a large number of significant differences
between devices in HRV indices during exercise. However, the effect size was small to
medium and of little practical relevance in the case of MHR. When observing RR (ip),
PLF (n) and PHF (n) signals, the percentage of subjects not reaching excellent agreement
between devices (CCC > 0.90) increased with exercise intensity and was higher for PHF (n)
than for PLF (n). Cluster analysis revealed that phenotypic characteristics like age, body
composition and fitness level influenced HRV measurements as well as the differences
between PolarH7 and ECG. In particular, CLUSTER D, composed of subjects with low
fitness level, high age and high trunk fat percentage, was the group with the lowest number
Sensors 2021, 21, 902 10 of 14
of subjects obtaining excellent agreement between devices for PHF (n) and with the highest
%Error for time- and frequency-domain HRV indices.
The large number of significant differences in the temporal domain HRV indices
(MHR, SDNN and RMSSD) between PolarH7 and ECG at all cycling stages could be due to
a small but consistent difference between devices. Specifically, PolarH7 values were usually
slightly lower than those measured by the ECG, which is supported by the obtained small
to medium effect sizes. In the case of MHR, the values measured by the two devices for
individual subjects were the same up to the 2nd-3rd decimal figure. Even if significant,
such differences between devices may not be meaningful in practice, as differences of less
than one beat per minute are below what has been reported as the smallest worthwhile
change in previous studies [37].
Regarding analysis of the full paired series of RR intervals, excellent agreement
between devices was found at rest, in accordance with previous validation studies of
PolarH7/H10 HR sensors [10,12]. Also, our results confirmed that the agreement between
devices decreased with the intensity of exercise, as previously reported [11,12]. Despite
this reduction, Gilgen-Ammann et al. proposed Polar H10 as the gold standard for RR
interval assessment during intense activities for HR and HRV evaluation [12]. It should be
noted, however, that a reduced set of ten healthy, lean and physically fit volunteers was
considered in [12], whereas here we investigated a larger set of volunteers with a broader
range of ages, body compositions and fitness levels. This may explain why we found a
more noticeable reduction in the agreement between devices during exercise.
Frequency-domain HRV indices, including PLF and PHF, were not usually inves-
tigated in previous studies validating PolarH7/H10 HR sensors. Nevertheless, these
frequency-domain signals were evaluated in the previous Polar RS800 model, reporting
that differences between devices increased with exercise intensity and were higher for PHF
than for PLF [17]. In the present study, PLF showed excellent agreement at rest and during
the whole exercise test, meaning that PolarH7 can follow HR oscillations up to 0.15 Hz. Still,
the percentage of subjects reaching excellent agreement for PLF at the highest intensities
(81% with CCC > 0.9 at 80% of HRmax) was lower than in [17] (96% with Pearson correla-
tion coefficient > 0.8 at 80–100% of VO2max), possibly due to the greater heterogeneity of
the present population sample. In the case of PHF, we found that PolarH7 and ECG showed
disagreement at the highest intensities, in accordance with results reported for Polar RS800,
possibly due to a multifactorial etiology, including the higher respiratory frequency and
higher noise level during exercise, the processing performed by Polar when a beat cannot
be detected and the effect of the body characteristics of the subjects [17]. Since both PHF,
reflecting vagal modulation of cardiac activity, and its highly correlated time-domain HRV
measures, such as RMSSD [38], are commonly used to monitor the autonomic status before,
during and after exercise [39], a note of caution on the interpretation of results obtained
from PolarH7 is suggested, especially at exercise intensities greater than 70% of HRmax.
Our results from clustering analysis confirmed the hypothesis that the phenotypic
characteristics of the subjects are one of the causes for the observed differences between
PolarH7 and ECG devices [17]. As initially postulated, CLUSTER D, containing subjects
with low fitness, high age and high trunk fat percentage, was the one showing the highest
%Error for HRV indices, reaching 50% error in PHF and 30% error in RMSSD for intensities
greater than 70% of HRmax. Nevertheless, even in CLUSTER D, some subjects presented
excellent agreement between devices, confirming that the characteristics of the subjects are
not the only cause of disagreement. Future studies should clarify other possible reasons
underlying the observed differences between devices.
The recovery from exercise was the time period when the lowest CCC values were
measured, especially for PLF and PHF signals. To our knowledge, this is the first time
that PolarH7 validity has been analyzed during sitting recovery. The lack of agreement
between devices could be due to the noisy signal recorded by PolarH7 in some volunteers,
as illustrated in Figure 3. Consequently, despite the correction algorithms, 10% of PLF
signals and 27% of PHF signals presented very low agreement (CCC < 0.1). Based on these
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results, assessment of HRV, particularly PLF and PHF, during the recovery period may not
be reliable if PolarH7 is used. This is in line with Schneider et al., who recommended
evaluation of HR recovery rather than evaluating post-exercise HRV [7].
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tre t s i it ti s
r s t study has several main strengths. One of them is the phenotypic variety of
the 67 volunteers. HR sensor validation studies are often carried out in groups of 20, or even
fewer, young, lean, healthy and physically fit volunteers [10–12], and in these conditions
it may be easier to detect RR intervals. Therefore, our larger sample of 20- to 70-year-old
subjects with varied physical conditions is much more heterogeneous and representative of
HR sensor users. Secondly, our assessment of PolarH7 validity as a function of phenotypic
characteristics, including age, is particularly relevant considering that the older population
is growing all around the world and more so in Europe [40], with advanced age being
associated with changes in body composition and reduced cardiorespiratory fitness [41,42].
Taking into account these associations, cluster analysis was used to evaluate how the
concurrence of these characteristics in the volunteers could affect HRV measurements
obtained from PolarH7. In third place, cardiorespiratory fitness and the excess of body fat
are strong predictors of mortality and risk of cardiovascular disease, being age the main
risk factor for multimorbidity [40,42]. Accordingly, it is of special interest to evaluate the
validity of these devices in subjects with these phenotypic characteristics. As discussed in
the introduction of the study, the applications of HRV in the evaluation and management
of a wide range of diseases are growing. The use of these inexpensive and simple to use
devices could be a very useful tool for E-health in primary care. HRV measures that can be
reliably assessed by HR sensors like PolarH7 need to be established so that interpretations
can be safely made. Last but not least, all our body measurements and signal recordings
were performed in the laboratory, under homogeneous conditions, enabling the control of
confounding factors and the reproducibility of the study.
On the other hand, some limitations need to be acknowledged. According to the meta-
analysis by Dobbs et al., the degree of absolute error between portable devices and ECG
measurements was larger among studies involving a greater number of female subjects [9].
Here, only men were studied so that sex was not a confounding variable. Further research
over other populations including not only women but also black/African would allow
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confirming the results obtained by this study in wider populations. Another potential
limitation is that PolarH7 has been superseded by the Polar H10 band. Even so, millions
of users still wear a PolarH7 band and the performance of both bands seems to be similar
during stationary exercise [43]. Future studies could extend the research here presented to
the analysis of other HR sensors.
5. Conclusions
Three major findings have emerged from the present study. First, assessment of HR
and HRV in a relatively large and heterogeneous sample has confirmed that PolarH7 can
accurately measure mean HR and low-frequency oscillations (up to 0.15 Hz) of HR at
rest and during exercise. However, disagreement between PolarH7 and ECG exists when
evaluating high-frequency HR oscillations during moderate-to-high intensity exercise.
Second, the validity of PolarH7 measurements during sitting recovery has been studied
for the first time. The results of the present research support the notion that PolarH7 is
appropriate to study HR recovery rather than post-exercise HRV. Third, clustering analysis
shows that the agreement between PolarH7 and ECG devices varies depending on the
characteristics of the subjects regarding age, body composition and fitness level. Our results
point to the need of ensuring phenotypic variety in any validation studies of HR sensors.
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